Kalshi drug trial prediction markets raise ethical concerns among attorneys
Kalshi Inc.'s opening of prediction markets for clinical drug trials has raised compliance concerns for attorneys, including one source's warning of 'a moral hazard.' The markets allow traders to bet on pharmaceutical trial outcomes. Attorneys flagged ethical qualms about whether financial incentives could influence trial conduct or disclosure, creating potential conflicts with research integrity and patient welfare.
The ethical friction around Kalshi's drug trial markets arrives while the platform is already embattled on multiple legal fronts. Kalshi faces state gambling suits in Ohio and Tennessee after a Sixth Circuit ruling stripped its federal preemption shield, plus New York litigation against rival Polymarket that uses the same gambling-framing theory.
Any new scandal tied to patient welfare or research integrity would give state attorneys general fresh ammunition to argue that event contracts belong under state gambling laws, not CFTC jurisdiction. A single headline about trial manipulation would harden judicial and public opinion faster than lobbying can soften it. Kalshi's legal team must now police drug trial market integrity while funding parallel state defenses. The first adverse finding on either front sets the compliance bar every competitor races to clear.